NRC Health financials
$21.05+4.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.4M | $34.8M | $35.2M | $34.6M | $34.0M | $33.6M | $36.9M | $35.8M | $35.0M | $35.3M | $38.0M | $37.9M |
| Gross profit | $21.8M | $21.2M | $21.3M | $22.2M | $21.1M | $20.5M | $22.6M | $20.5M | $21.6M | $35.3M | $38.0M | $37.9M |
| Gross margin | 61.7% | 60.8% | 60.4% | 64.2% | 61.9% | 61.1% | 61.1% | 57.3% | 61.7% | 100.0% | 100.0% | 100.0% |
| Operating income | -$3.2M | $5.6M | $4.7M | $7.7M | $1.6M | $8.6M | $9.6M | $8.0M | $8.9M | $8.8M | $11.7M | $10.0M |
| Net income | -$3.3M | $3.2M | $1.5M | $4.1M | -$106.0K | $5.8M | $6.6M | $5.7M | $6.2M | $6.4M | $8.9M | $7.9M |
| Net margin | −9.3% | 9.3% | 4.2% | 11.9% | −0.3% | 17.2% | 17.8% | 15.9% | 17.6% | 18.0% | 23.3% | 20.8% |
| Diluted EPS | $-0.15 | $0.14 | $0.07 | $0.18 | $-0.01 | $0.25 | $0.28 | $0.24 | $0.26 | $0.27 | $0.36 | $0.32 |
| EBITDA | -$1.1M | $7.7M | $6.8M | $9.9M | $3.3M | $10.1M | $11.1M | $9.5M | $10.4M | $10.2M | $11.7M | $11.5M |
| Operating cash flow | $1.4M | $7.2M | $7.2M | $13.8M | -$1.1M | $6.6M | $6.4M | $9.4M | $6.8M | $12.0M | $11.7M | $9.8M |
| Free cash flow | $62.0K | $5.3M | $6.1M | $10.2M | -$4.1M | $3.7M | $1.9M | $7.8M | $1.5M | $7.9M | $7.9M | $5.3M |
| Diluted shares | 22.0M | 21.9M | 21.8M | 22.1M | 22.7M | 23.0M | 23.3M | 23.7M | 23.9M | 24.0M | 24.5M | 24.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.3M | $2.5M | $4.1M | $2.2M | $5.3M | $2.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $90.0M | $78.0M | $79.0M | $80.0M | $81.0M | $65.2M |
| Total assets | $136.2M | $134.6M | $134.9M | $135.7M | $141.4M | $135.2M |
| Total liabilities | $129.6M | $121.1M | $120.9M | $121.4M | $120.1M | $105.5M |
| Shareholders' equity | $6.5M | $13.5M | $14.0M | $14.3M | $21.3M | $29.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology